

Resource Summary Report

Generated by [dkNET](#) on Aug 5, 2026

Hsd:Athymic Nude-Foxn1^{nu}

RRID:IMSR_ENV:HSD-069

Type: Organism

Proper Citation

RRID:IMSR_ENV:HSD-069

Organism Information

URL: <https://www.envigo.com/model/hsd-athymic-nude-foxn1nu>

Proper Citation: RRID:IMSR_ENV:HSD-069

Description: Mus musculus with name Hsd:Athymic Nude-Foxn1^{nu} from IMSR.

Species: Mus musculus

Notes: gene symbol note: forkhead box N1; outbred stock|mutant stock: Foxn1

Affected Gene: forkhead box N1

Genomic Alteration: nude

Catalog Number: ENV:HSD-069

Database: Envigo an Inotiv Company

Database Abbreviation: ENV

Availability: live

Organism Name: Hsd:Athymic Nude-Foxn1^{nu}

Record Creation Time: 20250513T061850+0000

Record Last Update: 20260801T055441+0000

Ratings and Alerts

No rating or validation information has been found for Hsd:Athymic Nude-Foxn1^{nu}.

No alerts have been found for Hsd:Athymic Nude-Foxn1^{nu}.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: Envigo an Inotiv Company

Usage and Citation Metrics

We found 102 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zangari J, et al. (2025) D-cysteine impairs tumour growth by inhibiting cysteine desulfurase NFS1. *Nature metabolism*, 7(8), 1646.

Kalva SK, et al. (2025) LED-based optoacoustic tomography of mice. *Journal of biomedical optics*, 30(4), 040501.

de Goñi I, et al. (2025) Generation and Characterization of Novel Contilisant+Tubastatin a Multitarget Small Molecules Against Glioblastoma. *Pharmaceutics*, 17(12).

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 1069.

Artetxe-Zurutuza A, et al. (2025) Generation and validation of a novel multitarget small molecule in glioblastoma. *Cell death & disease*, 16(1), 250.

Manabe T, et al. (2025) Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies. *Research square*.

Kesh K, et al. (2025) Targeting Triple-Negative Breast Cancer with Momordicine-I for Therapeutic Gain in Preclinical Models. *Cancers*, 17(14).

Feng Y, et al. (2025) Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3537.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. *Molecular cancer therapeutics*, 24(9), 1415.

Wei Q, et al. (2025) Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3. *iScience*, 28(3), 111931.

Park JS, et al. (2025) L1CAM signaling through planar cell polarity generates SOX2 + metastatic progenitors in lung adenocarcinoma. *bioRxiv : the preprint server for biology*.

Baglamis S, et al. (2025) Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. *iScience*, 28(5), 112403.

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. *Cancer research communications*, 5(3), 458.

Figuerola-Bou E, et al. (2025) KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma. *Cancer research*, 85(22), 4485.

Tai Y, et al. (2024) FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer. *EMBO molecular medicine*, 16(8), 1957.

Uluç N, et al. (2024) Non-invasive measurements of blood glucose levels by time-gating mid-infrared optoacoustic signals. *Nature metabolism*, 6(4), 678.

Ko?nik W, et al. (2024) Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice. *International journal of molecular sciences*, 25(1).

Lin CC, et al. (2024) PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. *Nature communications*, 15(1), 2287.

Staniszewska AD, et al. (2024) Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(7), 1338.

Bootsma S, et al. (2024) Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. *Cell reports. Medicine*, 5(5), 101523.